GlassScriptPhysician profile
Prashanth Vallabhanath
NPI 1386626372
$1,284.49
in general payments reported to CMS, 2019-2025
10 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $110 · 2021: $181 · 2023: $103 · 2024: $399 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $405.66 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $301.02 | 2019-2021 | |
| Rxsight INC | $155.01 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Alcon Vision LLC | $136.93 | 2023-2024 | Clareon, Rocklatan, Hydrus Microstent |
| Allergan, INC. | $125.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $110.43 | 2020 | |
| Omeros Corporation | $19.79 | 2019 | |
| Abbvie INC. | $18.78 | 2024 | |
| New World Medical,INC. | $11.87 | 2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Vallabhanath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.